Search icon
Learn, Analyse & Invest
only with
Orca logoArrow icon
+91
Download Orca
orca play storeorca apple store
To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Cipla Ltd.

Cipla

0.00

0.00 (0.00)%

NSE

BSE

EX-DatePurpose
14 05 2021 Dividend & Audited Results
05 08 2021 Quarterly Results
26 10 2021 Quarterly Results
25 01 2022 Quarterly Results
10 05 2022 Dividend & Audited Results
29 07 2022 Quarterly Results
04 11 2022 Quarterly Results
25 01 2023 Quarterly Results
12 05 2023 Audited Results & Quarterly Results & Final Dividend
26 07 2023 Quarterly Results
27 10 2023 Quarterly Results
22 01 2024 Quarterly Results (Revised)
25 01 2024 Quarterly Results
10 05 2024 Audited Results & Final Dividend
29 10 2024 Quarterly Results
13 05 2025 Audited Results & Final Dividend
25 07 2025 Quarterly Results

News

01-SEP-2022

Cipla’s arm to pick up 13.10% stake in Jiangsu

Post-acquisition, Cipla EU’s stake in the subsidiary, will increase to 93.10%

11:06 AM
02-MAR-2024

Cipla transfers Generics Business Undertaking to Cipla Pharma and Life Sciences

The company had received approval from board of directors to transfer Generics Business Undertaking

09:33 AM
03-FEB-2024

Cipla acquires additional stake in GoApptiv

Accordingly, Cipla will now hold 22.99% stake on a fully diluted basis in GoApptiv

10:25 AM
03-FEB-2025

Cipla to invest in Cipla Medpro South Africa Proprietary

The investment is expected to be completed on or before February 28, 2025

05:23 PM
03-MAY-2023

USFDA conducts routine cGMP inspection at manufacturing facility of Cipla’s arm

The inspection concluded with zero Form 483 observations

09:31 AM
05-APR-2024

USFDA concludes routine cGMP inspection at Cipla’s manufacturing facility in Patalganga

On conclusion of the inspection, the company has received 6 inspectional observations in Form 483

09:24 AM
05-AUG-2022

Cipla’s arm to acquire additional 19.16% stake in Cipla Maroc

Upon completion of acquisition, Cipla EU will hold 79.16% stake in the JV Co and balance 20.84% stake will be held by Cooper Pharma

09:29 AM
05-JUL-2022

USFDA conducts pre-approval inspection at Cipla’s Indore plant

The company has received 2 observations on FDA Form 483 with respect to ANDA filed for the product to be manufactured at the said plant

10:22 AM
05-NOV-2022

Cipla reports 12% rise in Q2 consolidated net profit

Total consolidated income of the company increased by 6.65% at Rs 5951.49 crore for Q2FY23

11:40 AM
05-SEP-2023

Cipla’s arm to acquire 100% stake in Actor Pharma

This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities and leverage cost synergies in the South African market

09:39 AM
06-JAN-2024

Cipla’s arm to incorporate JV Company in USA

The JV entity is being incorporated with an objective of commercialising novel cell therapy products in USA, Japan and EU region

10:53 AM
06-NOV-2023

Cipla gets nod to transfer generics business undertaking

The Board of Directors of the company at its meeting held on November 06, 2023 have inter alia, approved the same

05:21 PM
07-JAN-2025

Cipla launches mobile application for asthma screening

The mobile application is designed to enable the first line of screening for asthma in India

02:56 PM
07-MAR-2024

Cipla’s arm completes sale of entire shareholding in Wellthy

The consideration received from such sale is Rs 59.71 lakh

09:25 AM
07-SEP-2022

Cipla receives USFDA’s approval for Lenalidomide Capsule

The product will be available for shipping soon

02:51 PM
08-AUG-2022

Cipla eyeing to scale up US core formulations sales

Besides, the company is betting big on digitisation

05:30 PM
08-FEB-2024

Cipla’s arm completes acquisition of 100% equity stake in Actor Pharma

Accordingly, Actor will now be a wholly owned step-down subsidiary of the Company

09:20 AM
10-FEB-2025

USFDA classifies Cipla’s Bengaluru manufacturing facility as Voluntary Action Indicated

USFDA had conducted routine current Good Manufacturing Practices inspection at Cipla’s said facility from November 07 to November 13, 2024

10:20 AM
10-JUL-2023

Cipla’s arm recalling six batches of Albuterol Sulfate inhalation Aerosol in US

These six batches were distributed nationwide to wholesalers and retailers

04:54 PM
11-APR-2025

Cipla gets USFDA’s final approval for generic cancer drug

The product is expected to be launched in H1 FY 2025-26 in the United States of America

09:23 AM
11-DEC-2023

Cipla’s arm recalls one lot of Vigabatrin for oral solution USP 500 mg

The affected lot is NB301030, with an expiration date of March 2025

09:50 AM
11-OCT-2022

Cipla’s Indore OSD plant designated by WEF as ‘Advanced 4IR Lighthouse’

The organization is amongst the first pharmaceutical companies in India & Asia to be part of the Global Lighthouse Network.

04:34 PM
12-MAY-2023

Cipla reports 41% rise in Q4 consolidated net profit

Total consolidated income of the company increased by 10.32% at Rs 5873.93 crore for Q4FY23

04:27 PM
13-DEC-2024

Cipla secures approval for distribution, marketing of Afrezza Inhalation Powder in India

This is the first and only noninjectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus

12:39 PM
13-MAY-2025

Cipla reports 30% rise in Q4 consolidated net profit

The total consolidated income of the company increased by 9.46% at Rs 7019.15 crore for Q4FY25

05:02 PM
14-NOV-2024

USFDA concludes inspection at Cipla’s manufacturing facility in Bengaluru

On conclusion of the inspection, the Company received 8 observations in Form 483

09:40 AM
15-DEC-2023

Cipla to further invest Rs 42 crore in GoApptiv

With the completion of this deal, Cipla’s total stake in GoApptiv will increase to 22.99% on a fully diluted basis

12:30 PM
15-JUL-2022

Cipla’s arm inks definitive agreements to acquire Endura Mass

CHL shall immediately initiate the distribution and marketing of the said products pending the closure of the proposed acquisition

09:19 AM
15-MAR-2023

Cipla to sell 51.18% stake in Cipla Quality Chemical Industries

The proposed sale is expected to be completed by May 31, 2023

09:25 AM
15-NOV-2023

Cipla’s arms complete sale of entire 51.18% stake in CQCIL

Accordingly, CQCIL has now ceased to be a subsidiary of the company with effect from November 14, 2023

03:29 PM
16-APR-2024

Cipla’s arm signs agreement for acquisition of business undertaking from Ivia Beaute

This strategic move is aligned with Cipla’s focus on enhancing its consumer healthcare and wellness portfolio

09:20 AM
16-FEB-2024

Cipla ties up with CSIR-CDRI

The collaboration aims to leverage the combined expertise and resources of both organisations to develop a safe and efficacious drug for fungal keratitis

10:41 AM
16-MAY-2023

Cipla to sell entire stake of 51% in Saba Investment

Consideration to be received from such sale/disposal is $6.50 million

09:28 AM
18-JAN-2023

Cipla launches Cippoint for non-communicable diseases, infectious disease

Cippoint aims to enable smaller healthcare establishments provide an accurate point-of-care testing experience

10:42 AM
18-JUN-2022

Cipla signs definitive agreements for acquisition of 21.05% stake in Achira Labs

This investment will facilitate a Cipla entity’s strategic participation in the Poe diagnostics and AMR space

09:30 AM
18-NOV-2023

Cipla executes facility demand guarantee for extending general banking facilities

The company has executed a Facility Demand Guarantee of South African Rand 945 million

03:29 PM
19-MAY-2025

Cipla’s arm’s Mahape facility classified as VAI by USFDA

USFDA had conducted the inspection at said facility from February 18 to February 20, 2025

10:30 AM
20-FEB-2023

Cipla gets 8 inspectional observations from USFDA for Pithampur facility

USFDA has conducted a cGMP inspection at Cipla’s Pithampur manufacturing facility

09:58 AM
20-MAY-2025

Cipla’s arm inks pact to acquire 26% stake in AMPIN Energy C&I Eighteen

The total consideration to be paid for the said acquisition is up to Rs 1.46 crore

12:21 PM
20-NOV-2023

Cipla’s Pithampur manufacturing facility gets warning letter from USFDA

The Company will respond to the Warning Letter within the stipulated timelines and work closely with the USFDA

09:49 AM
21-APR-2025

Cipla’s arm’s Goa facility classified as VAI by USFDA

USFDA had conducted the inspection at said facility from January 14 to January 20, 2025

10:10 AM
21-FEB-2025

USFDA concludes cGMP inspection at analytical testing facility of Cipla’s arm

On conclusion of the inspection, Sitec received two observations in Form 483

10:07 AM
21-FEB-2025

Cipla gets USFDA’s final nod for Nilotinib Capsules

Nilotinib is an oncology category product in capsule form for oral consumption

10:18 AM
21-JAN-2025

Cipla’s arm gets one observation for Goa facility

USFDA has conducted an inspection at the manufacturing facility of Medispray Laboratories

11:27 AM
21-SEP-2023

USFDA issues 5 inspectional observations to New York facility of Cipla’s arm

The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time

10:23 AM
22-AUG-2022

Cipla’s arm recalls 7992 bottles of Difluprednate Ophthalmic Emulsion in US market

The recalling of the lot is due to ‘lack of assurance of sterility’

09:57 AM
22-JUL-2025

Cipla signs definitive agreements for investment in iCaltech Innovations

iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus, with a core focus on respiratory care

09:20 AM
23-JAN-2024

Cipla’s arms incorporate wholly owned subsidiary in Mexico

Mexicip is incorporated with an objective of sale and distribution of pharmaceutical drugs in Mexico

03:12 PM
23-JAN-2024

Cipla reports 32% rise in Q3 consolidated net profit

Total consolidated income of the company increased by 14.58% at Rs 6788.44 crore for Q3FY24

02:26 PM
23-SEP-2022

Cipla gets EIR from USFDA for Indore plant

The USFDA had conducted product-specific pre-approval inspection at the Indore plant on June 27 and July 1

09:59 AM
24-NOV-2022

USFDA designates Cipla’s Goa plant as ’Official Action Indicated’

The USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved

03:09 PM
25-JAN-2023

Cipla reports 7% rise in Q3 consolidated net profit

Total consolidated income of the company increased 6.36% at Rs 5,924.53 crore for Q3FY23

04:21 PM
25-OCT-2022

Cipla’s arm recalling 9,041 cartons of Arformoterol Tartrate Inhalation Solution

The company is recalling the affected lot due to ‘lack of assurance of sterility: environmental monitoring failure’

11:04 AM
26-JUL-2023

Cipla reports 41% rise in Q1 consolidated net profit

Total consolidated income of the company increased by 18.01% at Rs 6,465.18 crore for Q1FY24

03:51 PM
26-SEP-2024

Cipla’s arm to acquire 6.9% stake held by Jiangsu Xidi Pharmaceuticals in China-based unit

Upon completion of the transaction, Cipla Jiangsu will become a wholly owned step-down subsidiary of the Company

12:44 PM
27-FEB-2024

Cipla secures approval to market novel antibiotic plazomicin in India

Plazomicin’s introduction in India underscores Cipla’s proactive response to the urgent global challenge of antimicrobial resistance

04:57 PM
27-JUL-2023

Cipla’s associate company incorporates wholly owned subsidiary

The creation of Pactiv as a separate entity allows GoApptiv to segregate its business into distinct sectors i.e., technology and pharmaceuticals

09:49 AM
27-MAR-2024

Cipla partners with Sanofi India

Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium

10:46 AM
27-OCT-2023

Cipla reports 45% rise in Q2 consolidated net profit

Total consolidated income of the company increased by 15.17% at Rs 6854.47 crore for Q2FY24

02:30 PM
27-SEP-2023

Cipla launches drone-powered critical medicine delivery in Himachal Pradesh

The firm aims to deliver medicines for cardiac, respiratory and other essential chronic therapies as part of the initiative

11:30 AM
28-DEC-2022

Cipla eyeing higher capital expenditure on automation for three more years

The company has started its investment journey on the automation front two years ago and has already been recognised for its work by multiple bodies

06:15 PM
28-JAN-2025

Cipla reports 47% rise in Q3 consolidated net profit

Total consolidated income of the company increased by 7.46% at Rs 7294.58 crore for Q3FY25

04:42 PM
28-NOV-2023

Cipla’s arm acquires additional 15.10% stake in Cipla Maroc SA

Accordingly, Cipla EU will now hold 75.10% stake in the JV Co.

11:53 AM
29-AUG-2022

Cipla gets 6 observations from USFDA for Goa plant

There are no data integrity observations

09:48 AM
29-AUG-2022

Cipla dissolves step down wholly owned subsidiary

Cipla Med pro Holdings was a dormant entity and this dissolution will not affect performance or revenue of the company

10:48 AM
29-NOV-2022

Cipla launches Leuprolide Acetate Injection Depot 22.5mg

Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection

09:22 AM
29-OCT-2024

Cipla’s consolidated net profit rises 13% in Q2FY25

Consolidated total income of the company increased by 5.65% at Rs 7,241.63 crore for Q2FY25

03:51 PM
30-DEC-2022

Cipla’s arm signs definitive agreements for equity investment in Ethris GmbH

A collaboration agreement is signed concurrently with the definitive agreement, which paves a path to market Ethris’ innovative portfolio in Cipla’s key emerging markets

09:41 AM
30-MAY-2025

Cipla’s arm acquires 26% stake in AMPIN Energy C&I Eighteen

Earlier, Jay Precision Pharmaceuticals had entered into Share Purchase, Subscription and Shareholder’s Agreement

02:20 PM
30-MAY-2025

Cipla’s arm incorporates new wholly owned subsidiary in Germany

CiplaRna has been incorporated with the objective of establishing a laboratory for mRNA-based formulation and drug development support

04:14 PM
30-SEP-2023

Cipla divests 51% stake in Saba Investment, UAE

Cipla, Saba Investment, UAE and Shibham Group Holding, UAE have executed Share Purchase agreement on September 28, 2023

10:16 AM
31-MAY-2025

USFDA concludes cGMP inspection at Cipla’s Bengaluru manufacturing facility

On conclusion of the inspection, the company received one observation in Form 483

10:40 AM
Enrich money logo